Welcome to the ePoster Viewing Panel of AICOG 2025

Author- Dr. Ankita G. Khiste (Junior Resident in Department of OBGY, GMCH Chh. Sambhajinagar), Dr. Shrinivas Gadappa (Professor and Head of Department of OBGY, GMCH Chh. Sambhajinagar. ) ABSTRACT Aims and Objectives- To study the efficacy and safety of Ferric Carboxymaltose 1 gm Injection in treatment of iron deficiency anaemia in pregnancy. Introduction- Nutritional Iron deficiency (ID) and iron deficiency anemia (IDA) in pregnancy are global health issues, affecting around 30% of women in high-resourced countries, and increasing to over 50% of women in low-resourced countries, negatively affecting both maternal and fetal outcomes. There is increasing data suggesting that newer intravenous formulations are safe and effective in the second and third trimesters and should be strongly considered in pregnant individuals without optimal response to oral iron repletion. Single dose of Intravenous administration of ferric carboxymaltose results in transient elevations in serum iron, serum ferritin and transferrin saturation, and, ultimately, in the correction of haemoglobin levels and replenishment of depleted iron stores and can effectively correct iron deficiency anaemia in pregnancy. Inclusion criteria- 1. Pregnant women ready to sign the informed consent form for participation in study. 2. Pregnant female >18 years of age visiting to department of Obstetrics and Gynecology in their 2nd trimester of gestation. 3. Documented Iron deficiency anemia with Hb < 10 gm/dL and Ferritin level <30 mcg/L 4. Pregnant women eligible for IV Iron including FCM injection. Exclusion criteria- 1. Pregnant women not ready to sign the informed consent form for participation in study. 2. Pregnant women beyond >24 weeks of gestation. 3. Any other type of anemia apart from Iron Deficiency anemia. 4. Evidence of iron overload conditions (e.g. hemochromatosis / hemosiderosis). 5. Any malignancy. 6. Presence of active liver disease/ HBV or HCV infection, CKD, HIV infection / AIDS, asthma, or rheumatoid arthritis. Methodology- A prospective interventional single centre study was conducted at GMCH Chh. Sambhajinagar. Pregnant women visiting our institute at 24 weeks of gestation with Hb levels <10g/dl and peripheral smear showing microcytic hypochromic/normochromic changes is diagnosed as a case of iron deficiency anaemia and treated with Intravenous injection of Ferric carboxymaltose 1g in 250ml Normal saline infused over 15 mins. If Hb levels <7g/dl, additionally serum ferritin and TSAT levels are calculated and anaemia is treated accordingly with Inj. FCM. Patient is followed up 4 weekly till labour and efficacy of inj FCM is noted if patient shows response to treatment by rise in Hb levels, ferritin levels or TSAT values, patient?s and baby?s condition status and her post delivery lab values. Results- Total number of cases studied over a period of one year, nov 2023-nov 2024 were 30, which were diagnosed with iron deficiency anaemia in their 2nd trimester and were treated with single dose of 1gm iv Inj FCM at 24 weeks of gestation. Out of which 16 patients delivered normally/ by caeserean section with Hb levels>10g/dl 14 patients are ANC and are maintaining their Hb values> 10g/dl as per follow up. Discussion- Single dose intravenous infusion of inj. Ferric carboxymaltose (FCM) can correct iron deficiency anaemia in the second or third trimester of pregnancy. It rapidly improves haemoglobin levels and replenishes depleted iron stores and also improves health related quality of life (HQLI) in pregnant patients with iron-deficiency anaemia. It was well tolerated in clinical trials. Conclusion- Ferric carboxymaltose is, therefore, an effective option in the treatment of moderate iron-deficiency anaemia and in patients for whom oral iron preparations are ineffective or cannot be administered.